Johnson & Johnson Medical Devices Companies fait l'acquisition d'Orthotaxy afin de développer la nouvelle génération de plateforme de chirurgie robotique assistée pour l'orthopédie.
Johnson & Johnson — Wikipédia
Johnson & Johnson to spin off consumer arm to focus on medical division | Healthcare industry | The Guardian
J&J Makes a $16.6 Billion Bet on Heart Pumps to Lift Medical-Device Sales - WSJ
J&J medical devices and diagnostics sales by franchise 2020-2022 | Statista
Mercy Collaborates with Johnson & Johnson Medical Devices Companies | Mercy
Le sous-traitant Jabil reprend 14 sites de Johnson & Johnson - VIPress.net
Medical Devices Products | Johnson & Johnson
J&J Becomes the Newest Competitor in the LAA Space
Medical Device Sales Overview Guide: Johnson & Johnson
Johnson & Johnson Will Break Itself Up Into Two Companies - The New York Times
J&J, HP team up for 3-D printing of personalized healthcare products | Fierce Biotech
Johnson & Johnson MedTech France | LinkedIn
Résultats : J&J se redresse avant une année charnière
Johnson Johnson Medical Products Company In Markham Ontario Stock Photo - Download Image Now - iStock
Johnson & Johnson MedTech acquires heart implant company Laminar for $400m - Medical Device Network
Johnson & Johnson se tourne vers Wall Street pour valoriser sa division santé grand public
J&J to buy cardio technology company Abiomed for $16.6B - The San Diego Union-Tribune
 "J&J to buy cardiovascular technology Abiomed in USD 16.6B deal")
J&J to buy cardiovascular technology Abiomed in USD 16.6B deal
État-major : Johnson & Johnson Medical Devices
Johnson and Johnson Medical Devices Companies | HT Medical Devices
J&J says it will split into two companies in 2022
J&J is latest big pharma, device company to call it splits with consumer health - MedCity News
:max_bytes(150000):strip_icc()/GettyImages-1164571110-5aac4eab835f43658d1daaaa8fff9675.jpg "J&J Beats Profit Estimates on Pharmaceutical, Medtech Sales as COVID-19 Shot Revenue Slows")
J&J Beats Profit Estimates on Pharmaceutical, Medtech Sales as COVID-19 Shot Revenue Slows
